Outcomes and Benefits of Using Twice Daily Nebulised Hypertonic Saline in T2-Low and T2-High Asthma With Bronchial Hypersecretion: A Retrospective Cohort Study
4 affiliations
- 1General Surgery, Wrexham Maelor Hospital, Wrexham, GBR
- 2Cardiology, Wrexham Maelor Hospital, Wrexham, GBR
- 3Otolaryngology, Wrexham Maelor Hospital, Wrexham, GBR
- 4Respiratory Medicine, Wrexham Maelor Hospital, Wrexham, GBR
Abstract
Objective
Patients with T2-low and T2-high asthma have limited treatment options. Our study aims to evaluate the efficacy of nebulised hypertonic saline (HS) as an adjunctive treatment in this cohort. Specifically, the study aims to evaluate whether HS is tolerated in these patients, given the historical concerns with HS-induced bronchoconstriction. Additionally, it aims to determine whether nebulised HS reduces the frequency of exacerbations and hospital admissions in patients with T2-low and T2-high asthma.
Methods
This retrospective cohort study reviewed adults with T2-low and T2-high asthma with a bronchial hypersecretion phenotype who underwent a successful trial of nebulised HS across two district general hospitals within Betsi Cadwaladr University Health Board in the United Kingdom between February 2023 and August 2025. We included patients who successfully tolerated the initial HS trial and remained on treatment for at least 12 months. Of the 48 people who passed the initial HS tolerance test, only 44 went on to continue the treatment for over a year. The clinical data, including asthma exacerbations requiring primary care treatment or hospital admissions, were compared between 12 months prior to starting treatment and 12 months after HS initiation. Pre- and post-treatment exacerbation frequencies and hospital admissions were compared using the paired Wilcoxon signed-rank test, with a statistical significance of p < 0.05.
Results
Of the 48 patients who passed the trial of nebulised HS, 44 remained on treatment after one year. The mean number of asthma exacerbations decreased significantly from 2.18 in the year before HS initiation to 1.20 in the year after treatment (p < 0.001). Mean hospital admissions due to acute asthma exacerbations significantly decreased, from 0.43 to 0.15 (p-value 0.006). Eleven patients (25%) were commenced on biologic therapy during the year following HS initiation.
Conclusion
Patients with T2-low and T2-high asthma who were started on long-term nebulised HS tolerated treatment well, and most remained on therapy at one year. Comparing the 12 months before and after starting HS, we found a statistically significant reduction in both exacerbations and hospital admissions. These findings suggest a potential role for nebulised HS as an adjunctive treatment in this patient group. However, this was an observational study, so we cannot establish causality, and confounding factors such as initiation of biologic therapy may have an influence. The findings are also limited as patients included are only from two hospitals, which results in reduced confidence in the generalisability of the findings to the wider population with the same diagnosis. Large-scale, prospective, controlled studies are required to confirm the efficacy of nebulised HS in this population.
Related
- Diagnostic yield of fiberoptic bronchoscopy-guided bronchial biopsies for suspected lung cancer in intensive care unit: A 10-year retrospective study
- Restrictive hypertonic saline resuscitation is associated with less intestinal injury after hemorrhagic shock in rats and with coordinated changes in MALAT1, miR-145-5p, and BNIP3 expression
- MVB Maturation Responsive to KRASG12D/TP53R175H Co‐mutations Fuels Extracellular Vesicle‐hypersecretion Phenotype to Aggravate Lymphangiogenesis and Lymphatic Metastasis
- Less Invasive Surfactant Administration Compared With Intubation-Surfactant-Extubation (INSURE), Nebulised Surfactant, and Continuous Positive Airway Pressure (CPAP) Alone in Preterm Infants With Respiratory Distress Syndrome: A Systematic Review.
- Ability of intravenous small-volume hypertonic sodium bicarbonate, sodium chloride, and glucose solutions to rapidly reverse electrocardiographic abnormalities in hyperkalemic calves with neonatal diarrhea.
BibTeX
@article{waddon2026outcomes,
title = {{Outcomes and Benefits of Using Twice Daily Nebulised Hypertonic Saline in T2-Low and T2-High Asthma With Bronchial Hypersecretion: A Retrospective Cohort Study}},
author = {Joseph Waddon and Rebekah Emmas and Erin McInally and Charlotte Hawkins and Katie Kemp},
journal = {Cureus},
year = {2026},
month = oct,
doi = {10.7759/cureus.118883},
url = {https://europepmc.org/article/PMC/PMC13723077},
note = {CC BY},
}
RIS
TY - JOUR
TI - Outcomes and Benefits of Using Twice Daily Nebulised Hypertonic Saline in T2-Low and T2-High Asthma With Bronchial Hypersecretion: A Retrospective Cohort Study
AU - Joseph Waddon
AU - Rebekah Emmas
AU - Erin McInally
AU - Charlotte Hawkins
AU - Katie Kemp
PY - 2026
DA - 2026/10/31
JO - Cureus
DO - 10.7759/cureus.118883
UR - https://europepmc.org/article/PMC/PMC13723077
AB - Objective Patients with T2-low and T2-high asthma have limited treatment options. Our study aims to evaluate the efficacy of nebulised hypertonic saline (HS) as an adjunctive treatment in this cohort. Specifically, the study aims to evaluate whether HS is tolerated in these patients, given the historical concerns with HS-induced bronchoconstriction. Additionally, it aims to determine whether nebulised HS reduces the frequency of exacerbations and hospital admissions in patients with T2-low and T2-high asthma. Methods This retrospective cohort study reviewed adults with T2-low and T2-high asthma with a bronchial hypersecretion phenotype who underwent a successful trial of nebulised HS across two district general hospitals within Betsi Cadwaladr University Health Board in the United Kingdom between February 2023 and August 2025. We included patients who successfully tolerated the initial HS trial and remained on treatment for at least 12 months. Of the 48 people who passed the initial HS tolerance test, only 44 went on to continue the treatment for over a year. The clinical data, including asthma exacerbations requiring primary care treatment or hospital admissions, were compared between 12 months prior to starting treatment and 12 months after HS initiation. Pre- and post-treatment exacerbation frequencies and hospital admissions were compared using the paired Wilcoxon signed-rank test, with a statistical significance of p < 0.05. Results Of the 48 patients who passed the trial of nebulised HS, 44 remained on treatment after one year. The mean number of asthma exacerbations decreased significantly from 2.18 in the year before HS initiation to 1.20 in the year after treatment (p < 0.001). Mean hospital admissions due to acute asthma exacerbations significantly decreased, from 0.43 to 0.15 (p-value 0.006). Eleven patients (25%) were commenced on biologic therapy during the year following HS initiation. Conclusion Patients with T2-low and T2-high asthma who were started on long-term nebulised HS tolerated treatment well, and most remained on therapy at one year. Comparing the 12 months before and after starting HS, we found a statistically significant reduction in both exacerbations and hospital admissions. These findings suggest a potential role for nebulised HS as an adjunctive treatment in this patient group. However, this was an observational study, so we cannot establish causality, and confounding factors such as initiation of biologic therapy may have an influence. The findings are also limited as patients included are only from two hospitals, which results in reduced confidence in the generalisability of the findings to the wider population with the same diagnosis. Large-scale, prospective, controlled studies are required to confirm the efficacy of nebulised HS in this population.
SN - 2168-8184
ER -